Home / Industry News / 2012 / Accelrys Acquires Aegis Analytical Corp. for $30 million in Cash

Accelrys Acquires Aegis Analytical Corp. for $30 million in Cash

Source: PharmaManufacturing.com

Oct 30, 2012

Sacbee.com

Show More Content

More News:

Pharma in review: trending stories 9/13/19

09/13/2019

Most popular Pharma Manufacturing stories from the past seven days.
Vertex to sell cystic fibrosis drugs in Scotland

09/12/2019

Amid Vertex’s continuing drug pricing battle with British regulators, the drugmaker has signed a deal to make two of its cystic fibrosis drugs available in Scotland.
Bayer reduces management board amid ongoing company shake-up

09/12/2019

Bayer’s quest to reduce its workforce has traveled all the way up into the company’s highest ranks.
Sanofi forks over $260M to end diabetes partnership

09/12/2019

Sanofi will pay Lexicon Pharmaceuticals $260 million to terminate a partnership related to the development of a diabetes drug.
Mallinckrodt offloads BioVectra for $250 million

09/10/2019

The company has agreed to sell its contract manufacturing unit to alleviate some of its debt woes as it faces a myriad of opioid lawsuits
FDA OKs Xeris Pharma low blood sugar pen

09/10/2019

The company announced positive results from two of its Phase 3 clinical studies on the investigational ready-to-use, room-temperature stable liquid glucagon rescue pen at the American Diabetes Association’s 78th Scientific Sessions
Novartis CEO pledges to proactively speed up disclosing data integrity issues

09/09/2019

The company head promised to voluntarily notify the FDA within five business days of receipt of any credible allegation related to data integrity impacting any pending application
Experimental Lilly med shrank nearly 70% of tumors in lung cancer trial

09/09/2019

The drug LOXO-292 was acquired by the drugmaker in the beginning of the year when it took over Loxo Oncology for $8 billion
Novartis investigational lung cancer therapy grabs breakthrough status

09/09/2019

The U.S. FDA has granted Breakthrough Therapy designation to Novartis' capmatinib, which the drugmaker aims to file for approval later this year to treat a mutated form of lung cancer.
Amgen experimental lung cancer drug shows promise in study

09/08/2019

More than half of patients with an advanced form of lung cancer initially responded to an experimental Amgen drug that targets a genetic driver of the disease.

All news

Pharma Manufacturing

Accelrys Acquires Aegis Analytical Corp. for $30 million in Cash

Mallinckrodt offloads BioVectra for $250 million

The company has agreed to sell its contract manufacturing unit to…

Amgen experimental lung cancer drug shows promise in study

More than half of patients with an advanced form of lung cancer initially…

Novartis investigational lung cancer therapy grabs breakthrough status

The U.S. FDA has granted Breakthrough Therapy designation to Novartis'…

Bayer reduces management board amid ongoing company shake-up

Bayer’s quest to reduce its workforce has traveled all the way up into…

Experimental Lilly med shrank nearly 70% of tumors in lung cancer trial

The drug LOXO-292 was acquired by the drugmaker in the beginning of the…

Pfizer recalls migraine drug for possible microbial contamination

Pfizer has recalled two lots of migraine drug Relpax after finding those…

Boehringer pharma head to step down

Allan Hillgrove, the board member responsible for the company's human…

FDA widens generic drug recall probe beyond heart meds

The FDA is reportedly expanding its investigation related into impurities…

Blockbuster-bound Lilly drug wins another FDA nod

Eli Lilly’s Taltz has been given the go-ahead for a new indication,…

FDA warns Chinese company for drug manufacturing data integrity violations

The organization sent Ningbo Huize Commodity a warning letter for…

The Highest — and Lowest — Ranked Places to Work in Big Pharma

How pharma companies fair on Glassdoor.

Merck to cut jobs, close plants with $1.2B restructuring plan

Merck and Co. has created a restructuring plan it says is designed to…

Torrent hit with Form 483

The FDA found that in hundreds of cases, batches at Torrent’s plant did…

Anti-vaxxers turn to potatoes

A new and weird rumor has surfaced in the anti-vaccine movement: potatoes…

Pharma's budding opportunity

Why the industry is forming bonds with CBD